Sigmovir Biosystems

Executive Summary

Sigmovir Biosystems, Inc. (SBI) is a privately held biotechnology company headquartered in Rockville, Maryland, that specializes in the cotton rat model for human infectious disease research. Founded in 2015, SBI leverages this unique animal model—which is permissive to a wide range of human pathogens—to offer contract research services for testing vaccines and therapeutics. The company also supplies cotton rats and related reagents to the scientific community, supporting pathogenesis studies and advancing biomedical research. As a niche CRO, Sigmovir benefits from the growing demand for preclinical testing services, particularly for respiratory viruses like RSV and influenza, where the cotton rat model is considered highly predictive. While the company does not have disclosed financials or a public ticker, its specialized expertise positions it as a valuable partner for pharmaceutical and biotech firms developing infectious disease interventions. However, its reliance on contract revenue and limited scalability outside its core model present risks.

Upcoming Catalysts (preview)

• Q3 2026Major Contract Award for RSV or Influenza Vaccine Testing70% success
• Q1 2027Expansion of Cotton Rat Model to Emerging Pathogens (e.g., Nipah, Lassa)40% success
• Q4 2026Partnership with Large Pharma for COVID-19 Therapeutic Testing50% success